KBC Group NV Has $30.29 Million Stock Position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

KBC Group NV grew its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 3.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 243,938 shares of the specialty pharmaceutical company's stock after acquiring an additional 7,620 shares during the quarter. KBC Group NV owned 0.40% of Jazz Pharmaceuticals worth $30,285,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. IFP Advisors Inc bought a new position in Jazz Pharmaceuticals in the fourth quarter worth $25,000. Quadrant Capital Group LLC raised its stake in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after buying an additional 101 shares in the last quarter. Elequin Capital LP lifted its holdings in shares of Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after acquiring an additional 183 shares during the period. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at about $28,000. Finally, Allianz SE bought a new stake in Jazz Pharmaceuticals in the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Trading Down 0.7%

Shares of JAZZ traded down $0.78 during trading hours on Monday, reaching $106.12. The stock had a trading volume of 728,509 shares, compared to its average volume of 825,856. The company has a market cap of $6.42 billion, a P/E ratio of 14.15, a P/E/G ratio of 4.61 and a beta of 0.33. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $148.06. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28. The firm has a 50-day moving average of $108.63 and a 200 day moving average of $119.53.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The business had revenue of $897.84 million during the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a net margin of 11.86% and a return on equity of 26.62%. The firm's revenue was down .5% on a year-over-year basis. During the same period in the previous year, the firm posted $2.68 earnings per share. On average, sell-side analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Insider Activity at Jazz Pharmaceuticals

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the transaction, the chief executive officer directly owned 440,307 shares of the company's stock, valued at $54,487,991.25. This trade represents a 0.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Seamus Mulligan bought 100,000 shares of the stock in a transaction that occurred on Friday, May 9th. The stock was bought at an average cost of $98.26 per share, for a total transaction of $9,826,000.00. Following the transaction, the director owned 100,000 shares of the company's stock, valued at $9,826,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold 3,000 shares of company stock valued at $355,925 in the last quarter. Corporate insiders own 4.30% of the company's stock.

Analyst Ratings Changes

JAZZ has been the subject of several analyst reports. Needham & Company LLC reissued a "buy" rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Morgan Stanley dropped their price objective on shares of Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Robert W. Baird lowered their target price on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. Finally, HC Wainwright upped their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $184.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.